Positive results in Phase III trial of Invokana for T2D

Results from a new 52-week analysis of Phase III results show Invokana (canagliflozin), from Janssen Pharmaceuticals, provides substantial improvements in glycemic control in patients with Type 2 Diabetes who are inadequately controlled on metformin and a sulfonylurea. Results from the study (known as DIA3002) showed that canagliflozin, at both the 100 mg and 300 mg doses, lowered glucose levels (percent changes, -0.74 and -0.96 vs. 0.01, respectively) and provided greater reductions in secondary endpoints of body weight (percent changes, -2.2 and -3.2 vs. -0.9, respectively) and blood pressure (-3.7 and -2.9 mmHg vs. 0.1 mmHg, respectively) compared to placebo.

Results were presented by Guillame Charpentier, MD, Head of the Department of Diabetes at the Sud-Francilien Hospital in France, at the 49th European Association for the Study of Diabetes. Invokana was approved for Type 2 Diabetes by the FDA in March 2013 and has been recommended for approval by the CHMP.